Free Trial Information
BioCentury | Dec 4, 2020
Finance

Dec. 3 Quick Takes: Israeli digital health firm closes $170M fund; plus BioAge, newco Rubedo, Portal Innovations, OliX

...with Trammell Crow Co. to develop the project.  Financing to support new RNA synthesis GMP facility for OliX OliX Pharmaceuticals Inc....
...Investment.   TARGETSHIF-PH (EGLN) – Hypoxia-inducible factor prolyl hydroxylasePTGDR1 (DP1) – Prostaglandin D2 receptor subtype DP1 BC Staff OliX Pharmaceuticals Inc. BioAge...
Read More
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

...Cytovia Therapeutics Inc. hired Wei Li as acting CSO. She was chief development officer of OliX Pharmaceuticals Inc....
Read More
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...NASDAQ:CNST) 7/18/18 $60.0 $385.5 $103.4 -73% Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) 7/17/18 $117.3 $406.4 $720.9 77% OliX Pharmaceuticals Inc....
Read More
BioCentury | Jul 20, 2018
Financial News

RNAi company OliX lists in Korea

...degeneration and retinal fibrosis, and OLX701 to treat liver fibrosis. OliX Pharmaceuticals Inc. (KOSDAQ:226950), Suwon, Korea Jaime De Leon OLX201 OLX301 OliX Pharmaceuticals Inc. Connective...
Read More
BioCentury | Jul 17, 2018
Financial News

RNAi company OliX lists in Korea

...treat wet age-related macular degeneration and retinal fibrosis, and OLX701 to treat liver fibrosis. Jaime De Leon OLX201 OLX301 OliX Pharmaceuticals Inc. Connective...
Read More
BioCentury | Sep 6, 2016
Company News

Management tracks

...Samarsky CSO, effective Sept. 14. He was SVP of technology and global business development at OliX Pharmaceuticals Inc....
Read More
Items per page:
1 - 6 of 6
BioCentury | Dec 4, 2020
Finance

Dec. 3 Quick Takes: Israeli digital health firm closes $170M fund; plus BioAge, newco Rubedo, Portal Innovations, OliX

...with Trammell Crow Co. to develop the project.  Financing to support new RNA synthesis GMP facility for OliX OliX Pharmaceuticals Inc....
...Investment.   TARGETSHIF-PH (EGLN) – Hypoxia-inducible factor prolyl hydroxylasePTGDR1 (DP1) – Prostaglandin D2 receptor subtype DP1 BC Staff OliX Pharmaceuticals Inc. BioAge...
Read More
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

...Cytovia Therapeutics Inc. hired Wei Li as acting CSO. She was chief development officer of OliX Pharmaceuticals Inc....
Read More
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...NASDAQ:CNST) 7/18/18 $60.0 $385.5 $103.4 -73% Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) 7/17/18 $117.3 $406.4 $720.9 77% OliX Pharmaceuticals Inc....
Read More
BioCentury | Jul 20, 2018
Financial News

RNAi company OliX lists in Korea

...degeneration and retinal fibrosis, and OLX701 to treat liver fibrosis. OliX Pharmaceuticals Inc. (KOSDAQ:226950), Suwon, Korea Jaime De Leon OLX201 OLX301 OliX Pharmaceuticals Inc. Connective...
Read More
BioCentury | Jul 17, 2018
Financial News

RNAi company OliX lists in Korea

...treat wet age-related macular degeneration and retinal fibrosis, and OLX701 to treat liver fibrosis. Jaime De Leon OLX201 OLX301 OliX Pharmaceuticals Inc. Connective...
Read More
BioCentury | Sep 6, 2016
Company News

Management tracks

...Samarsky CSO, effective Sept. 14. He was SVP of technology and global business development at OliX Pharmaceuticals Inc....
Read More
Items per page:
1 - 6 of 6